Use of calcifediol in bariatric surgery patients.

Sustained release 25-hydroxyvitamin D3 administration addresses vitamin D deficiency and secondary hyperparathyroidism post-bariatric surgery by maintaining optimal serum levels and improving bone health, effectively preventing related complications.

JP7590184B2Active Publication Date: 2024-11-26OPKO IRELAND GLOBAL HOLDINGS LTD(GB)
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020554174
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-03
Filing Date
2019-04-03
Publication Date
2024-11-26
Estimated Expiration
2039-04-03

AI Technical Summary

Technical Problem

Bariatric surgery often leads to vitamin D deficiency and secondary hyperparathyroidism due to malabsorption and impaired digestion, resulting in complications such as osteomalacia, osteoporosis, and bone loss, which existing supplementation methods fail to adequately address.

Method used

Administering sustained release 25-hydroxyvitamin D3 to patients before and after bariatric surgery to maintain optimal serum levels and prevent deficiencies, thereby treating or preventing conditions like secondary hyperparathyroidism and increasing bone mineral density.

Benefits of technology

The sustained release formulation effectively normalizes serum 25-hydroxyvitamin D levels, reduces parathyroid hormone concentrations, and enhances bone mineral density without causing hypocalcemia or other side effects, addressing the deficiencies and complications associated with bariatric surgery.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Methods and compositions for treating bariatric surgery patients and for treating or preventing complications associated with such patients are disclosed. [Selection diagram] None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS Benefit of priority under 35 U.S.C. §119(e) is hereby claimed from U.S. Provisional Patent Application No. 62 / 652,038, filed April 3, 2018, the disclosure of which is incorporated herein by reference in its entirety.

[0002] The present disclosure generally relates to the treatment of bariatric surgery patients with 25-hydroxyvitamin D3. The present disclosure also relates to the treatment or prevention of one or more complications of vitamin D insufficiency or deficiency associated with obesity and bariatric surgery, such as secondary hyperparathyroidism and osteomalacia. [Background technology]

[0003] Bariatric surgery has been shown to be an effective intervention for weight loss in obese patients. However, morbid obesity and subsequent surgical interventions often lead to nutritional deficiencies, including vitamin D deficiency, as measured by serum total 25-hydroxyvitamin D. A recent review article (Chakhtoura et al., Metabolism, 65(4) p.574-85, April 2016) reported that 29 of 51 observational studies had mean preoperative 25-hydroxyvitamin D concentrations below 30 ng / mL, and 17 of those studies had mean 25-hydroxyvitamin D concentrations below 20 ng / mL. With very few exceptions, mean 25-hydroxyvitamin D concentrations remained below 30 ng / mL after bariatric surgery despite various vitamin D supplementation regimens.

[0004] Vitamin D deficiency in this population is due to several factors, including those related to obesity itself, those related to the type of surgical intervention, and those related to the outcome of the surgical intervention. Regarding the first factor, an inverse correlation has been observed between body mass index (BMI) and serum total 25-hydroxyvitamin D. Despite normal absorption, it has been shown that in obese patients, vitamin D is stored in fat, resulting in reduced bioavailability, and it has also been proposed that the low serum total 25-hydroxyvitamin D is the result of volumetric dilution. Obese patients have also been shown to have reduced expression of 1α-hydroxylase and 25-hydroxylase in skin and visceral adipose tissue. Bariatric surgery has also been shown to affect serum total 25-hydroxyvitamin D concentrations. In malabsorptive procedures, fat malabsorption contributes to deficiency of fat-soluble vitamin D. Bypass of one or more of the major sites of vitamin D absorption in the small intestine also contributes to vitamin D deficiency, as does digestive disturbance. Food intolerances associated with both bypass and restrictive procedures can also contribute to vitamin D deficiency.

[0005] Vitamin D deficiency in this population is associated with secondary hyperparathyroidism, osteomalacia, and other bone complications including bone loss evidenced, for example, by reduced bone mineral density.

[0006] Secondary hyperparathyroidism is a disease that develops mainly due to vitamin D deficiency. It is characterized by abnormally high blood levels of PTH, and in the absence of early detection and treatment, it becomes associated with parathyroid hyperplasia and a series of metabolic bone diseases. It has been reported as a complication of vitamin D deficiency associated with bariatric surgery. Insufficient vitamin D supply leads to reduced production of vitamin D prohormones (e.g., 25-hydroxyvitamin D3). Low production of vitamin D prohormones leads to reduced blood levels of 25-hydroxyvitamin D.

[0007] Deficiency of vitamin D prohormones can lead to chronically low blood levels of 1,25-dihydroxyvitamin D, as adequate renal hormone production cannot continue without the necessary precursors. Inadequate supplies of cholecalciferol and ergocalciferol result in a marked decrease in prohormone production, a condition often described by terms such as "vitamin D insufficiency," "vitamin D deficiency," or "hypovitaminosis D." Decreased serum concentrations of 1,25-dihydroxyvitamin D increase and ultimately cause excessive secretion of PTH through direct and indirect mechanisms. The resulting hyperparathyroidism leads to a marked increase in bone turnover and its sequelae, renal osteodystrophy, which may include osteitis fibrosa cysticum, osteomalacia, osteoporosis, extraskeletal calcification, and a variety of other associated disorders, such as bone pain, periarthritis, and Mockerberg sclerosis. Decreased serum concentrations of 1,25-dihydroxyvitamin D can also cause growth retardation with muscle weakness and skeletal deformities (most often seen in pediatric patients). Summary of the Invention

[0008] One aspect of the present disclosure provides a method of treating a patient who has undergone bariatric surgery by administering sustained release 25-hydroxyvitamin D3.

[0009] Another aspect of the present disclosure provides a method of treating secondary hyperparathyroidism in patients who have undergone bariatric surgery by administering sustained release 25-hydroxyvitamin D3.

[0010] Another aspect of the disclosure provides a method of treating refractory vitamin D insufficiency (VDI) in patients who have undergone bariatric surgery by administering sustained release 25-hydroxyvitamin D3. Refractory VDI is defined as serum total 25-hydroxyvitamin D below 30 ng / mL despite at least 3 months of treatment with at least 3,000 IU per day of either cholecalciferol or ergocalciferol.

[0011] Another aspect of the disclosure provides a method of treating or preventing one or more conditions in a patient who has undergone bariatric surgery by administering sustained release 25-hydroxyvitamin D3, such conditions being one or more of renal osteodystrophy, osteomalacia, osteitis fibrosa cysticum, osteoporosis, extraskeletal calcification, bone pain, periarthritis, Mockerberg sclerosis, muscle weakness, growth retardation, and skeletal deformities.

[0012] Another aspect of the present disclosure provides a method of increasing bone mineral density in patients undergoing bariatric surgery by administering sustained release 25-hydroxyvitamin D3.

[0013] Another aspect of the present disclosure is to prevent the development of more severe vitamin D deficiency and associated secondary hyperparathyroidism caused by bariatric surgery by administering sustained release 25-hydroxyvitamin D3 prior to surgery.

[0014] For the methods, articles and kits described herein, it is contemplated that optional features, including but not limited to components, compositional ranges thereof, alternatives, conditions, and steps, are selected from the various aspects, embodiments, and examples provided herein.

[0015] Further aspects and advantages will become apparent to those of ordinary skill in the art upon review of the following detailed description. While the method is susceptible to embodiment in various forms, the following description includes specific embodiments with the understanding that such disclosure is illustrative and is not intended to limit the invention to the specific embodiments described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Described herein are materials and methods for treating bariatric surgery patients, including treating or preventing one or more post-operative conditions in bariatric surgery patients.

[0017] The materials and methods are intended to include embodiments that include any combination of one or more of the optional additional elements, features, and steps detailed below, unless otherwise stated.

[0018] In jurisdictions that prohibit the patenting of methods performed on the human body, the meaning of "administering" a composition to a human subject shall be limited to prescribing a controlled substance for the human subject to self-administer by any technique (e.g., orally, inhalation, topical application, injection, insertion, etc.). The broadest reasonable interpretation consistent with any statute or regulation defining patentable subject matter is intended. In jurisdictions that do not prohibit the patenting of methods performed on the human body, "administering" a composition shall include the foregoing acts as well as methods performed on the human body.

[0019] As used herein, the term "comprising" indicates that other agents, elements, steps or features may be included in addition to those specified.

[0020] As used herein, "vitamin D insufficiency and deficiency" is generally defined as a serum total 25-hydroxyvitamin D concentration less than 30 ng / mL. Refractory VDI is defined as a serum total 25-hydroxyvitamin D less than 30 ng / mL despite at least 3 months of treatment with at least 3,000 IU per day of either cholecalciferol or ergocalciferol.

[0021] As used herein, "hypercalcemia" refers to a condition in a patient in which the corrected serum calcium concentration exceeds 10.2 mg / dL. The normal corrected serum calcium concentration in humans is approximately 8.6 to 10.2 mg / dL. As used herein, "hypocalcemia" refers to a condition in a patient in which the corrected serum calcium concentration is less than 8.6 mg / dL.

[0022] As used herein, the term "hyperphosphatemia" refers to the condition in a patient where the serum phosphorus concentration exceeds 4.6 mg / dL.

[0023] As used herein, the term 25-hydroxyvitamin D generally refers to forms of 25-hydroxyvitamin D, including 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and 25-hydroxyvitamin D4. In any of the methods described herein, it is contemplated that the use of 25-hydroxyvitamin D may comprise, consist of, or consist essentially of a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3. In any of the methods described herein, it is contemplated that the use of 25-hydroxyvitamin D may comprise, consist of, or consist essentially of 25-hydroxyvitamin D3.

[0024] As used herein, the term "total serum 25-hydroxyvitamin D" refers to the sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in serum.

[0025] As used herein, the term 1,25-dihydroxyvitamin D generally refers to forms of 25-hydroxyvitamin D, including 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3. The term "serum total 1,25-dihydroxyvitamin D" refers to the sum of 1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 in serum.

[0026] Although bariatric surgery is generally performed on obese patients for weight loss intervention, patients treated according to the methods described herein may also have undergone malabsorption-related surgery for another reason, such as, for example, intestinal cancer. Bariatric surgery is generally classified into two types, malabsorptive and restrictive, and combinations thereof. In malabsorptive procedures, ingested food bypasses the absorptive and / or secretory regions of the stomach, small intestine, or both the stomach and small intestine. In restrictive procedures, the volume of the stomach is significantly reduced. Types of bariatric surgery may include, for example, one or more of gastric bypass, gastroplasty, biliary pancreatic diversion, anastomosis, Roux-en-Y gastric bypass, gastroenteric anastomosis, pancreaticojejunostomy, gastrectomy, and jejunoileal bypass. Specific procedures may include, but are not limited to, gastric bypass, sleeve gastrectomy, adjustable gastric band, and biliary pancreatic diversion with duodenal diversion.

[0027] For example, in gastric banding, e.g., adjustable gastric banding, a silicone or inflatable band is placed around the upper stomach to form a small stomach pouch above the band, and the remaining stomach below the band is connected to the upper small pouch through an opening. The size of the opening between the upper stomach pouch and the remaining stomach can be adjusted, for example, by filling the band with sterile saline or removing saline from the band.

[0028] In the Roux-en-Y gastric bypass, the top of the stomach is divided from the remnant stomach to form a small stomach pouch. The first portion of the small intestine is then divided, and the lower end of the divided small intestine is elevated and connected to the newly formed small stomach pouch. The procedure is completed by connecting the top of the divided small intestine to the further down the small intestine so that gastric acid and digestive enzymes from the bypassed stomach and the first portion of the small intestine eventually mix with food. Ingested food thereby passes through the small stomach pouch into the connected portion of the small intestine, thereby bypassing the distal portion of the stomach and the first portion of the small intestine. In certain embodiments, the bypassed portion of the small intestine includes the duodenum. In another type of embodiment, the bypassed portion of the small intestine includes the duodenum and the proximal portion of the jejunum.

[0029] In a sleeve gastrectomy, the stomach is divided, for example, longitudinally. The volume of the stomach can be reduced, for example, by at least 70%, or 75%, or 80%, or 85%. The pyloric valve is preserved.

[0030] In a biliary pancreatic diversion procedure, a portion of the stomach, e.g., the distal horizontal section, is removed. The remaining portion of the stomach is connected to the lower portion of the small intestine, e.g., bypassing the entire duodenum, optionally all or part of the jejunum, and optionally the proximal portion of the ilium.

[0031] In biliary pancreatic diversion with duodenal diversion, a portion of the stomach is removed to form a small pouch. The small intestine is divided into two portions. The distal end of the small intestine, often at the ilium, is connected to the gastric pouch so that the proximal portion of the small intestine is bypassed. The excluded portion of the small intestine is connected to the small bowel, forming a common channel that drains into the colon.

[0032] Jejunoileal bypass is a completely malabsorptive procedure. The stomach is left intact. Typically, a portion of the proximal jejunum (e.g., 35 cm) is anastomosed to a terminal portion of the ileum (e.g., 10 cm).

[0033] As mentioned above, bariatric surgery often bypasses the preferred site of calcium and vitamin D absorption (i.e., the duodenum), putting patients at risk for altering calcium and vitamin D homeostasis.

[0034] Bariatric surgery is effective in treating obesity but is not without significant side effects. Macro- and micronutrient deficiencies are common in obese patients, one of which is VDI. The causes of VDI in obese patients are complex and related to obesity, as well as lifestyle and physiological factors other than diet and nutrient malabsorption. If left untreated, VDI can lead to SHPT, muscle weakness, and ultimately bone disease.

[0035] Besides vitamin D malabsorption due to bypass of the primary absorption site and digestive disorders, various factors contribute to VDI, as is common in obese patients. Studies have shown an inverse correlation between body mass index (BMI) and serum 25-hydroxyvitamin D concentrations. It has been hypothesized that obese patients have less exposure to sunlight, which is essential for the synthesis of vitamin D3, because obesity limits mobility. Furthermore, vitamin D is sequestered in adipose tissue and diluted with greater body weight. Obesity has also been associated with decreased hepatic synthesis of the vitamin D prohormone calcifediol (25-hydroxyvitamin D3), and increased expression of the vitamin D catabolic enzyme CYP24A1. In one class of embodiments, the patient is one who has undergone surgery that includes an element of bypass. In one aspect, the bypass includes a distal portion of the stomach. In another aspect, the bypass includes all or a portion of the duodenum. In another aspect, the bypass includes both the distal portion of the stomach and all or a portion of the duodenum. In another aspect, the bypass includes at least a proximal portion of the jejunum. In another embodiment, the bypass includes both the jejunum and all or a portion of the duodenum, hi another embodiment, the bypass includes a distal portion of the stomach, the duodenum, and at least a proximal portion of the jejunum.

[0036] The treatment described herein is intended for post-operative use in bariatric surgery patients. In another embodiment, the treatment described herein is intended for both pre-operative and post-operative use in bariatric surgery patients. The treatment can be used pre-operatively in such patients, as needed, for example, as part of a pre-operative routine. For example, pre-operative treatment can be started when a patient is considering bariatric surgery. Pre-operative treatment can be started when a patient is deemed eligible for bariatric surgery. In another example, pre-operative treatment can be started at the same time as other vitamin or multivitamin supplements as part of a pre-operative regimen. In another example, pre-operative treatment can be started at the same time as a pre-operative diet plan is started. As another example, pre-operative treatment can be started within a certain period of time before surgery, for example, 6 months before surgery, 30 days before surgery, 2 weeks before surgery, 5 days before surgery, or on the day of surgery. In any of the above methods, treatment (pre- or post-operative) can be optionally initiated in patients with total serum 25-hydroxyvitamin D concentrations of 30 ng / mL or less, or 30 ng / mL or less, or 20 ng / mL or less. In any of the above methods, treatment (pre- or post-operative) can be optionally initiated in patients with secondary hyperparathyroidism. In any of the above methods, treatment (pre- or post-operative) can be optionally initiated in patients with plasma intact parathyroid hormone (iPTH) concentrations above the upper limit of the laboratory reference range.

[0037] Bariatric surgery patients may be selected based on BMI and / or additional factors. For example, the patient may have a BMI greater than 40, or at least 45, or at least 50, or in the range of 50-100. Alternatively, the patient may have a BMI greater than 35, as well as one or more obesity-related diseases (e.g., heart disease, fatty liver, type 2 diabetes). In another embodiment, the patient may have a BMI greater than 30 and is undergoing a low-risk and / or minimally invasive procedure, such as a gastric band procedure. In another embodiment, the patient may be classified as overweight, greater than 100 pounds. In another embodiment, the patient may have a BMI less than 30 and have vitamin D deficiency. In another embodiment, the patient may have a BMI less than 30 and have secondary hyperparathyroidism. In another embodiment, the patient may have a BMI less than 30 and have both vitamin D deficiency and secondary hyperparathyroidism.

[0038] The patient treated by the methods described herein may be a patient with reduced expression of 25-hydroxylase in skin and / or visceral adipose tissue.The patient treated by the methods described herein may be a patient with reduced expression of 1α-hydroxylase in skin and / or visceral adipose tissue.The patient treated by the methods described herein may be a patient with reduced expression of 25-hydroxylase in liver.

[0039] The patient treated by the methods described herein may be a patient suffering from one or more conditions or disorders, including one or more of osteomalacia, renal osteodystrophy, osteitis fibrosa cysticum, osteoporosis, extraskeletal calcification, bone pain, periarthritis, Mockerberg sclerosis, muscle weakness, growth retardation, and skeletal deformity (e.g., common in pediatric patients).For example, the patient treated may be a patient diagnosed with one or more of the aforementioned conditions or disorders.

[0040] In another embodiment, the method may include treating or preventing one or more conditions or disorders including one or more of osteomalacia, renal osteodystrophy, osteitis fibrosa cysticum, osteoporosis, extraskeletal calcification, bone pain, periarthritis, Mockerberg sclerosis, muscle weakness, growth retardation, and skeletal deformities.

[0041] In the methods according to the present disclosure, patients are administered 25-hydroxyvitamin D (calcifediol) in an average amount of 30-150 mcg per day. Individual doses can range, for example, from 5 to 1,000 mcg. Calcifediol is more polar than vitamin D (cholecalciferol or ergocalciferol) and is therefore absorbed more quickly in the digestive tract. Furthermore, unlike vitamin D, calcifediol does not require 25-hydroxylation in the liver, which may be impaired in obese patients.

[0042] 25-hydroxyvitamin D can be administered on any suitable schedule. For example, the administration schedule can be daily, or every other day, or three times a week, or weekly.

[0043] 25-hydroxyvitamin D can be administered with or without food, or independently of food. In certain embodiments, 25-hydroxyvitamin D is administered without food, e.g., at bedtime, to reduce variability in 25-hydroxyvitamin D absorption due to food and / or food intolerance.

[0044] 25-hydroxyvitamin D can be administered without concomitant vitamin D therapy, e.g., in the absence of cholecalciferol, in the absence of ergocalciferol, in the absence of calcifediol, in the absence of calcifediol analogs, or in the absence of 1α-hydroxylated vitamin D compounds. Alternatively, 25-hydroxyvitamin D can be administered with up to 3,000 IU per day or 90,000 IU per month of vitamin D supplementation (i.e., the total amount of cholecalciferol and ergocalciferol administered for supplementation).

[0045] Treatment can include administering 25-hydroxyvitamin D without concomitant calcimimetic therapy, for example, in the absence of cinacalcet.

[0046] Treatment involves restricting elemental calcium (from diet and supplements) to less than 1500 mg per day.

[0047] Treatment can include administering 25-hydroxyvitamin D without a bone metabolic therapy, for example, in the absence of a bone metabolic therapy, such as, for example, bisphosphonates, denosumab, teriparatide, preotact, and calcitonin.

[0048] Cytochrome P450 inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole, may inhibit enzymes involved in vitamin D metabolism (CYP24A1 and CYP27B1) and may alter serum concentrations of 25-hydroxyvitamin D. Dosage adjustments of 25-hydroxyvitamin D administration may be necessary if a patient initiates or discontinues treatment with a strong CYP3A4 inhibitor.

[0049] Cholestyramine has been reported to decrease the intestinal absorption of fat-soluble vitamins and may impair the absorption of 25-hydroxyvitamin D. Dosage adjustments of 25-hydroxyvitamin D administration may be necessary when patients begin or discontinue treatment with cholestyramine.

[0050] Phenobarbital and other anticonvulsants or other compounds that stimulate microsomal hydroxylation decrease the half-life of 25-hydroxyvitamin D. Dosage adjustments of 25-hydroxyvitamin D administration may be necessary when patients begin or discontinue treatment with phenobarbital or other anticonvulsants.

[0051] The patient may have a plasma iPTH of 85 pg / mL or greater at the start of treatment.

[0052] The course of 25-hydroxyvitamin D therapy and / or dosage adjustments can be continued to achieve one or more therapeutic effects. For example, the method can include 25-hydroxyvitamin D therapy that increases serum total 25-hydroxyvitamin D to a concentration of at least 30 ng / mL, or at least 50 ng / mL, or at least 90 ng / mL, or at least 100 ng / mL, or greater than 100 ng / mL, or in the range of 100 ng / mL to 200 ng / mL, or maintains serum total 25-hydroxyvitamin D at a concentration of at least 30 ng / mL, or at least 50 ng / mL, or at least 90 ng / mL, or at least 100 ng / mL, or greater than 100 ng / mL, or in the range of 100 ng / mL to 200 ng / mL. In another embodiment, the method may include a 25-hydroxyvitamin D therapy that increases serum total 25-hydroxyvitamin D by at least 8 ng / mL, or more than 8 ng / mL, or more than 10 ng / mL, or more than 15 ng / mL, or more than 20 ng / mL, or more than 30 ng / mL, for example, in the range of 8 ng / mL to 200 ng / mL, or 15 ng / mL to 200 ng / mL. The method may include a 25-hydroxyvitamin D therapy that increases serum total 25-hydroxyvitamin D to such a concentration and / or by such an amount, for example, 6 months after surgery. The method may include a 25-hydroxyvitamin D therapy that increases serum total 25-hydroxyvitamin D to such a concentration and / or by such an amount, for example, 6 months after initiation of 25-hydroxyvitamin D therapy.

[0053] The method may include 25-hydroxyvitamin D therapy to reduce serum parathyroid hormone concentration. The method may include 25-hydroxyvitamin D therapy to reduce serum parathyroid hormone concentration by at least 10%, or at least 20%, or at least 30%, or more, compared to a pre-treatment baseline. The method may include 25-hydroxyvitamin D therapy to reduce serum parathyroid hormone concentration to a target concentration, for example, in the range of about 10 pg / mL to 65 pg / mL for adults and about 9 pg / mL to 52 pg / mL for pediatric patients. The method may include 25-hydroxyvitamin D therapy to maintain serum parathyroid hormone concentration below a threshold, for example, in the range of about 10 pg / mL to 65 pg / mL for adults and about 9 pg / mL to 52 pg / mL for pediatric patients. The method may include 25-hydroxyvitamin D therapy to increase bone mineral density, for example, to a T-score of at least -2.5, or greater than -2.5, or at least -2.0, or at least -1.5, or at least -1.0, or greater than -1.0. The method may include 25-hydroxyvitamin D therapy to reduce blood levels of bone resorption markers, for example, one or more of PTHrP, serum fibroblast growth factor 23 (FGF23), NTX, C-terminal cross-linked telopeptide of collagen type I (CTx), and tartrate-resistant acid phosphatase 5b (TRAP-5b, also known as TRAC-5b). The method may include 25-hydroxyvitamin D therapy to reduce blood levels of bone formation markers, for example, bone-specific alkaline phosphatase (BAP) or N-terminal propeptide of procollagen type 1 (P1NP). For example, blood levels of markers of bone resorption or bone formation may be reduced to within the reference range of laboratory measurement techniques. In another embodiment, blood levels of a marker of bone resorption or bone formation can be reduced by at least about 10%, or at least about 20%, or at least about 30%.

[0054] FGF23 concentrations in biological samples obtained from patients can be determined by various techniques known to those skilled in the art. For example, the concentrations of intact FGF-23 (iFGF23) and the median C-terminal FGF-23 (cFGF23) can be measured using ELISA kits available from IMMUTOPICS (San Clemente, Calif., USA). Measurements of the aforementioned species are preferably performed as serum concentrations, but concentrations can also be measured in plasma, serum, or other body fluids (e.g., saliva) or tissues. Normal iFGF23 concentrations range from 0 to 90 pg / mL in healthy adults (Fliser et al. J. Am. Soc. Nephrol. 18:2601-2608 (2007), Ibrahim et al. Int. Urol. Nephrol. 41(1):163-169 (2009)). Normal cFGF23 concentrations range from 0 to 85 reference units (RU) / mL in healthy adults (Tebbin et al. Mayo Clin. Proc. 80(6):745-751 (2005)).

[0055] In another embodiment, the method can include administering 25-hydroxyvitamin D therapy as described herein and without 1,25-dihydroxyvitamin D therapy.

[0056] 25-hydroxyvitamin D can be administered in any form or by any method, but in one embodiment, 25-hydroxyvitamin D can be administered by modified release methods and / or formulations, including, for example, sustained and / or delayed release embodiments. In another embodiment, 25-hydroxyvitamin D can be administered solely or primarily by sustained release (also known as extended release or time-release) methods and / or formulations. For example, sustained release can be achieved by oral dosage forms, or sustained release can be achieved by transdermal patches. In another embodiment, sustained delivery can be provided by slowly injecting the compound over time, for example, by slowly pushing intravenous delivery.

[0057] In one type of embodiment, 25-hydroxyvitamin D is administered orally. For example, 25-hydroxyvitamin D can be administered in an oral sustained release formulation. Alternatively, 25-hydroxyvitamin D can be administered in multiple doses over an extended period of time throughout the day in an oral immediate release formulation to produce a pharmacokinetic profile of serum 25-hydroxyvitamin D similar to that achieved by an oral sustained release formulation.

[0058] For example, a controlled release composition intended for oral administration can be designed to contain 25-hydroxyvitamin D2 and / or 25-hydroxyvitamin D3 at a concentration of 1-1000 μg per unit dose and can be formulated to provide a substantially constant release of 25-hydroxyvitamin D2 and / or 25-hydroxyvitamin D3 over an extended period of time, e.g., at least 4 hours, or at least 8 hours, or at least 12 hours, or at least 24 hours.

[0059] The preparation of sustained release forms of 25-hydroxyvitamin D suitable for oral administration can be carried out according to many different techniques. For example, one or more 25-hydroxyvitamin D compounds can be dispersed in a matrix, i.e., a selected mixture of rate-controlling components and excipients in a selected ratio can be dispersed in a matrix and optionally covered with a coating material. Alternatively, one or more different coating techniques can be utilized to control the release rate of 25-hydroxyvitamin D from pharmaceutical formulations. For example, the coating can gradually dissolve over time, thereby exposing the dosage form contents, optionally contained in the matrix, to the body fluids of the local environment. In certain embodiments, after the coating becomes permeable, 25-hydroxyvitamin D diffuses through the coating, for example, from the outer surface of the matrix contained within the coating. When 25-hydroxyvitamin D is exhausted or depleted at the surface of such a matrix, the underlying reserves begin to be depleted by diffusion through the matrix to the external solution. In another type of embodiment, the release of 25-hydroxyvitamin D through the permeable coating or structure is affected by the gradual disintegration or erosion of the matrix contained therein, for example, the solubility of one or more components of the matrix. In another type of embodiment, the release of 25-hydroxyvitamin D is by the gradual disintegration or erosion of the matrix, for example, the solubility of one or more components of the matrix, and / or by the lack of physical integrity, the absence of any coating or other structure surrounding the matrix. The dosage form may optionally further comprise another active agent in the same region as 25-hydroxyvitamin D or in a different region. For example, the additional active agent may include calcium.

[0060] In one embodiment, the formulation provides one or more 25-hydroxyvitamin D compounds within a matrix that releasably binds components for sustained release when exposed to the contents of the gastrointestinal tract, e.g., the stomach, small intestine, or colon.

[0061] In one embodiment of the present invention, a controlled release oral formulation of 25-hydroxyvitamin D is generally prepared according to the following procedure: A sufficient amount of 25-hydroxyvitamin D, e.g., calcifediol, is completely dissolved in a minimum volume of USP grade absolute ethanol (or other suitable solvent) and mixed with suitable amounts and types of pharmaceutical grade excipients to form a matrix that is solid or semi-solid at room temperature and at normal human body temperature. The matrix slowly disintegrates in the intestine and / or colon.

[0062] In a preferred formulation, the matrix binds the 25-hydroxyvitamin D compound(s) such that the 25-hydroxyvitamin D is released slowly and relatively steadily, e.g., substantially constantly, by simple diffusion and / or gradual breakdown into the contents of the small intestine and / or colon over a period of 4 to 8 hours or longer.

[0063] As noted above, the means for providing controlled release of 25-hydroxyvitamin D may be selected from any suitable controlled release delivery system, including any of the known controlled release delivery systems that deliver the active ingredient over a period of about 4 hours or more, including wax matrix systems, and the EUDRAGIT RS / RL system (Rohm Pharma, GmbH, Weiterstadt, Germany).

[0064] The wax matrix system provides a type of lipophilic matrix. The wax matrix system may utilize, for example, beeswax, white wax, sperm whale wax, or similar compositions. In certain embodiments, the wax is a non-digestible wax, for example, paraffin. The active ingredient(s) are dispersed in a wax binder, which slowly disintegrates in intestinal fluids to gradually release the active ingredient(s). The wax binder impregnated with 25-hydroxyvitamin D may be filled into a softgel capsule. The softgel capsule may include one or more gel-forming agents, for example, gelatin, starch, carrageenan, and / or other pharma-ceutically acceptable polymers. In one embodiment, a partially cross-linked soft gelatin capsule is used. Alternatively, a vegetable-based capsule may be used. In the wax matrix system, the active ingredient(s) are dispersed in a wax binder, which softens at body temperature and slowly disintegrates in intestinal fluids to gradually release the active ingredient(s). The system can suitably include a mixture of waxes, with optional additional oils, to achieve a melting point above body temperature but below the melting temperature of the selected formulation used to make the soft or hard capsule shell, or vegetable capsule shell, or other formulation used to make the shell casing or other coating.

[0065] Specifically, in a preferred embodiment, the wax selected for the matrix is ​​melted and thoroughly mixed. The desired amount of oil is then added, followed by thorough mixing and homogenization. The waxy mixture is then gradually cooled to a temperature just above its melting point. The desired amount of 25-hydroxyvitamin D dissolved in ethanol is uniformly distributed into the molten matrix, and the matrix is ​​filled into a capsule, for example, a vegetable-based or gelatin-based capsule. The filled capsule is optionally treated with a solution containing an aldehyde, such as acetaldehyde, for an appropriate time to partially crosslink the polymer, for example, gelatin, in the capsule shell when in use. The capsule shell is gradually crosslinked over a period of weeks, thereby becoming more resistant to dissolution in the contents of the stomach and upper intestine. If properly constructed, this gelatin shell will gradually dissolve after oral administration, and by the time it reaches the small intestine, it will be sufficiently porous (without completely disintegrating) to allow 25-hydroxyvitamin D to slowly diffuse out of the wax matrix into the contents of the small intestine and / or colon.

[0066] Examples of other lipid matrices suitable for use in the methods of the present invention include one or more of glycerides, fatty acids and fatty alcohols, and fatty acid esters.

[0067] The wax matrix may contain a stabilizing component that stabilizes the release characteristics of the dosage form over its expected shelf life. The stabilizing component may be a cellulose component, such as a cellulose ether, e.g., hydroxylpropylmethylcellulose.

[0068] In one embodiment, the formulation may include an oil vehicle for the 25-hydroxyvitamin D compound. Any pharma- ceutically acceptable oil may be used. Examples include animal (e.g., fish), vegetable (e.g., soybean), and mineral oils. The oil is preferably one that readily dissolves the 25-hydroxyvitamin D compound used. The oil vehicle may include mineral oil, particularly non-digestible oils such as liquid paraffin, and squalene. The ratio of wax matrix to oil vehicle may be optimized to achieve the desired release rate of the 25-hydroxyvitamin D compound. Thus, when a heavier oil component is used, relatively less wax matrix may be used, and when a lighter oil component is used, relatively more wax matrix may be used.

[0069] Another suitable controlled release oral drug delivery system is the EUDRAGIT RL / RS system in which the active 25-hydroxyvitamin D ingredient is formed into granules, for example, 25 / 30 mesh in size. The granules are then uniformly coated with a thin polymer lacquer, which is water insoluble but slowly water permeable. The coated granules can be mixed with optional additives, including one or more of antioxidants, stabilizers, binders, lubricants, processing aids, and the like. The mixture can be compressed into a hard, dry tablet that can be further coated prior to use, or can be poured into a capsule. When the tablet or capsule is swallowed and comes into contact with gastric and intestinal fluids, the thin lacquer begins to swell, slowly allowing the intestinal fluids to penetrate. As the intestinal fluids slowly penetrate the lacquer coating, the contained 25-hydroxyvitamin D is slowly released. By the time the tablet or capsule passes through the small intestine, about 4-8 hours or later, the 25-hydroxyvitamin D has been slowly, but completely, released. Thus, when ingested, the tablet continuously releases 25-hydroxyvitamin D, as well as any other active ingredients.

[0070] The EUDRAGIT system consists of a high-permeability lacquer (RL) and a low-permeability lacquer (RS). RS is a water-insoluble film-forming agent based on a neutral swellable methacrylate ester and a small amount of trimethylammonioethyl methacrylate chloride, with a molar ratio of quaternary ammonium groups to neutral ester groups of approximately 1:40. RL is also a water-insoluble swellable film-forming agent based on a neutral methacrylate ester and a small amount of trimethylammonioethyl methacrylate chloride, with a molar ratio of quaternary ammonium groups to neutral ester groups of approximately 1:20. The permeability of the coating, and therefore the time course of drug release, can be adjusted by changing the ratio of RS to RL in the coating material. For more information on the Eudragit RL / RS system, see the technical publications available from Rohm Tech, Inc. 195 Canal Street, Maiden, Mass., 02146 and K. Lehmann, D. Dreher “Coating of tablets and small particles with acrylic resins by fluid bed technology,” Int. J. Pharm. Tech. & Prod. Mfr. 2(r), 31-43 (1981), which are incorporated herein by reference.

[0071] Other examples of insoluble polymers include polyvinyl esters, polyvinyl acetals, polyacrylic esters, butadiene styrene copolymers, and the like.

[0072] The dosage form may also contain adjuvants such as preservatives or stabilizing adjuvants. For example, a preferred formulation contains 25-hydroxyvitamin D (e.g., about 30mcg, about 60mcg, or about 90mcg of 25-hydroxyvitamin D3), about 2% by weight absolute ethanol, about 10% by weight lauroyl polyoxyl glyceride, about 20% by weight solid paraffin, about 23% by weight glycerol monostearate, about 35% by weight liquid paraffin or mineral oil, about 10% by weight hydroxypropyl methylcellulose, and optionally a small amount of antioxidant preservative (e.g., butylated hydroxytoluene). The formulation according to the present invention may also contain other therapeutically valuable substances or may contain a mixture of two or more compounds specified in this specification and claims.

[0073] As an alternative to oral 25-hydroxyvitamin D, intravenous administration of 25-hydroxyvitamin D is also contemplated. In one embodiment, 25-hydroxyvitamin D is administered as a sterile intravenous bolus, optionally as a bolus injection of a composition that provides a sustained release profile. In another embodiment, 25-hydroxyvitamin D is administered via gradual injection / infusion, for example, over 1-5 hours, to provide a controlled or substantially constant release of 25-hydroxyvitamin D to DBP in the patient's blood. For example, the composition may be injected or infused over at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, or at least about 6 hours. In one embodiment, a composition intended for intravenous administration according to the present invention is designed to include a concentration of 1-100 mcg of 25-hydroxyvitamin D compound(s) per unit dose. Sterile isotonic formulations of 25-hydroxyvitamin D can be prepared by dissolving 25-hydroxyvitamin D in absolute ethanol, propylene glycol or another suitable solvent and combining the resulting solution with one or more surfactants, salts, and preservatives in an appropriate amount of water for injection. Such formulations can be administered slowly from a syringe, for example, via a heparin lock or by addition to a larger volume of sterile solution (e.g., saline) that is steadily infused over time.

[0074] Suitable sustained release dosage forms of 25-hydroxyvitamin D are described, such as in the following U.S. patents and published U.S. patent applications, the disclosures of which are incorporated by reference herein: 2010 / 0120728A1, 2010 / 0144684A1, 2013 / 0137663A1, 8,329,677, 8,361,488, 8,426,391, 8,962,239, and 9,861,644. EXAMPLES

[0075] The following examples are offered for illustrative purposes and are not intended to limit the scope of the present invention.

[0076] Example 1 Efficacy study in Roux-en-Y surgery patients The efficacy of oral sustained-release 25-hydroxyvitamin D3 in restoring serum total 25-hydroxyvitamin D to optimal concentrations (>30 ng / mL) and reducing parathyroid hormone concentrations will be examined in a 6-month study of adult male and female patients who are candidates for Roux-en-Y surgery for weight loss. In a controlled study, patients will be treated with sustained-release 25-hydroxyvitamin D3 (softgel capsules containing 25-hydroxyvitamin D3).

[0077] A total of 60 subjects will be enrolled in the study, all with evidence of SHPT, as defined by serum total 25-hydroxyvitamin D concentrations less than 30 ng / mL and serum intact parathyroid hormone concentrations greater than 70 pg / mL at enrollment. All subjects will receive multivitamin therapy including calcium (up to 1,000 mg per day) and cholecalciferol (3,000 IU per day) postoperatively and will refrain from other vitamin D therapy and significant exposure to sunlight. Serum total 25-hydroxyvitamin D, serum intact parathyroid hormone, serum calcium, serum phosphorus, urinary calcium, urinary phosphorus, and urinary creatinine will be measured starting on the day of surgery and at monthly intervals thereafter.

[0078] After 2 months, the daily calcium amount is maintained unchanged, the cholecalciferol supplement is discontinued, but daily sustained-release 25-hydroxyvitamin D3 (softgel capsules containing 30 μg of 25-hydroxyvitamin D3) is initiated and continued for 4 months.

[0079] At time zero and at months 1 and 2, the patient group had mean serum total 25-hydroxyvitamin D concentrations below 30 ng / mL, and the group had mean serum intact parathyroid hormone concentrations above 70 pg / mL. Postoperatively, there was only a modest increase in mean serum total 25-hydroxyvitamin D concentrations, with no significant difference in serum intact parathyroid hormone concentrations.

[0080] After initiation of treatment with sustained-release 25-hydroxyvitamin D3, there is a gradual but significant increase in the group's mean serum total 25-hydroxyvitamin D concentration and a progressive decrease in the mean serum intact parathyroid hormone concentration in the third month. By the end of treatment, at the six-month measurement, the group's mean serum total 25-hydroxyvitamin D concentration normalizes to greater than 30 ng / mL and the group's mean serum intact parathyroid hormone concentration is less than 65 pg / mL.

[0081] Example 2 Long-term efficacy study in Roux-en-Y surgery patients The efficacy of oral sustained-release 25-hydroxyvitamin D3 in restoring optimal serum total 25-hydroxyvitamin D concentrations (>30 ng / mL) and increasing bone mineral density will be examined in a 1-year study in adult male and female patients undergoing bariatric surgery for weight loss that included at least duodenal bypass. In a randomized, double-blind, controlled trial, patients will be treated with sustained-release 25-hydroxyvitamin D3 or cholecalciferol.

[0082] A total of 200 subjects will participate in the study. All subjects will be aged 18 years or older, have a bone mineral density T-score of -2.0 to -4.0 as assessed by dual-energy x-ray absorptiometry (DEXA), and a serum total 25-hydroxyvitamin D concentration of less than 30 ng / mL at enrollment. All subjects will receive a multivitamin regimen that includes calcium (1,000 mg per day) and either cholecalciferol (3,000 IU per day) or multiple sustained-release 25-hydroxyvitamin D3 (softgel capsules containing 30 μg of 25-hydroxyvitamin D3), and will abstain from other vitamin D therapy and significant sun exposure at the start of and continue through the end of the study.

[0083] After 3 months, the daily dose of 3 softgel capsules of 25-hydroxyvitamin D should remain unchanged in patients with serum total 25-hydroxyvitamin D between 50 and 90 ng / mL and should be increased by 1 capsule in patients with serum total 25-hydroxyvitamin D less than 50 ng / mL. In patients with documented elevated serum total 25-hydroxyvitamin D greater than 100 ng / mL or serum calcium greater than 10.3 mg / dL, the dose should be immediately reduced by 1 capsule per day.

[0084] Serum total 25-hydroxyvitamin D, plasma iPTH, serum calcium, serum phosphorus, urinary calcium, urinary phosphorus, and urinary creatinine will be measured from the day of surgery and at monthly intervals.Bone mineral density at 4 sites (total hip, femoral neck, radial 1 / 3, and lumbar spine) will be measured quarterly by DEXA.

[0085] After 6-9 months, all treated subjects demonstrate that serum total 25-hydroxyvitamin D concentrations remain essentially stable with continued dosing and rise to approximately 50-100 ng / mL with 25-hydroxyvitamin D3 treatment, or to approximately 5-25 ng / mL with vitamin D3 treatment. In patients treated with 25-hydroxyvitamin D3, the incidence of hypocalcemia and the severity of secondary hyperparathyroidism are significantly reduced once stable dosing is achieved. However, hypocalcemia and secondary hyperparathyroidism occur more frequently in patients treated with cholecalciferol. After 12 months of treatment, patients treated with sustained-release 25-hydroxyvitamin D3 demonstrate higher and more consistent serum concentrations of 25-hydroxyvitamin D3 and lower plasma iPTH concentrations than patients treated with cholecalciferol. We also see that patients treated with sustained-release 25-hydroxyvitamin D3 experienced a significant increase in bone mineral density compared with only a small change or decrease in bone mineral density in patients treated with cholecalciferol.Data from this study demonstrate that treatment with sustained-release 25-hydroxyvitamin D3 is effective in normalizing serum total 25-hydroxyvitamin D, reducing plasma iPTH concentrations, and increasing bone mineral density without causing unacceptable side effects related to calcium, phosphorus, or FGF23 metabolism.

[0086] Example 3 Long-term efficacy study in bariatric surgery patients The efficacy of oral extended-release 25-hydroxyvitamin D3 (ERC) in raising serum total 25-hydroxyvitamin D to ≥ 30 ng / mL and reducing plasma iPTH by at least 30% from pretreatment baseline will be examined in a 52-week study in male and female patients aged ≥ 18 years with refractory VDI who have undergone bariatric surgery. In a randomized, double-blind, controlled trial, patients will receive ERC or a matching placebo.

[0087] At screening, subjects will not have any disease or physical conditions that may compromise safety evaluations or prevent participation in the study, such as serum albumin ≤ 3.0 g / dL and serum transaminases (alanine aminotransferase [ALT], glutamic-pyruvic transaminase [SGPT], aspartate aminotransferase [AST], or glutamic-oxaloacetic transaminase [SGOT]) > 2.5 times the upper limit of normal.

[0088] At the initial screening visit, subjects will have a plasma iPTH of 70 pg / mL or greater if receiving cinacalcet, calcitriol, or other 1α-hydroxylated vitamin D analogs (paricalcitol or doxercalciferol), or a plasma iPTH of 85 pg / mL or greater if not receiving cinacalcet, calcitriol, or other 1α-hydroxylated vitamin D analogs (paricalcitol or doxercalciferol) and a serum total 25-hydroxyvitamin D of less than 30 ng / mL.

[0089] If otherwise eligible at visit 1, subjects will discontinue all further treatment with cinacalcet for the duration of the study and enter an 8-week washout period.

[0090] If otherwise eligible at visit 1, subjects will discontinue all further treatment with calcitriol or other 1α-hydroxylated vitamin D analogs for the duration of the study and enter an 8-week washout period.

[0091] If otherwise eligible at visit 1, subjects taking vitamin D supplementation at rates greater than 3,000 IU per day or 90,000 IU (2,250 mcg) per month will have their dose reduced to 3,000 IU per day or less for the duration of the study, followed by an 8-week washout period.

[0092] If indicated by prior use of cinacalcet, calcitriol, or other 1α-hydroxylated vitamin D analogs, or vitamin D supplementation at rates greater than 3,000 IU per day or 90,000 IU (2,250 mcg) per month, after an 8-week washout period, subjects will demonstrate plasma iPTH ≥ 85 pg / mL pg / mL, corrected serum calcium < 9.8 mg / dL, serum total 25-hydroxyvitamin D < 30 ng / mL, and serum phosphorus ≤ 5.5 mg / dL.

[0093] If otherwise eligible at visit 1, subjects consuming more than 1,500 mg of elemental calcium per day (from diet and supplements) will have their calcium intake reduced (to ≤1,500 mg per day) for the duration of the study.

[0094] If otherwise eligible at visit 1, subjects receiving bone metabolism therapies that may interfere with the study endpoints will discontinue use of these medications for the duration of the study.

[0095] After completing treatment, subjects will enter a 6-week follow-up (FU) observation period, so subjects will remain in the study for a maximum of 70 weeks (2-week screening, 8-week washout if necessary, 2-week baseline, 52 weeks of treatment with ERC capsules or matching placebo, and 6-week FU assessment).

[0096] Blood samples will be collected at weekly, 2-week, or monthly intervals during the pretreatment period, the 52-week treatment period, the 6-week posttreatment FU period, and at early termination (ET), if applicable. Primary parameters analyzed in collected samples include plasma iPTH, serum calcium (corrected for serum albumin), serum phosphorus, serum total 25-hydroxyvitamin D, serum calcifediol, serum 1,25-dihydroxyvitamin D3, and serum 24,25-dihydroxyvitamin D3 (24,25D3). Vital signs (VS) and AEs will be monitored at each study visit. Other parameters monitored less frequently include a brief physical examination (PE) and laboratory tests (hematology and clinical chemistry). Electrocardiograms (ECG; 12-lead) and bone mineral density assessments (by DEXA) will be obtained at baseline and end of treatment (EOT) only, or at ET. Additional parameters will be monitored at specified intervals, including serum FGF23 and serum bone turnover markers.

[0097] Subjects will begin with three capsules per day (two 30 mcg ERC capsules and one matching placebo capsule or three placebo capsules) at bedtime. After 12 weeks of treatment, subjects receiving ERC will have their dose titrated from 60 mcg to 90 mcg per day (three 30 mcg ERC capsules) provided that (a) plasma iPTH has not declined by at least 30% from treatment baseline and remains above 70 pg / mL, (b) corrected serum calcium is less than 9.8 mg / dL, and (c) serum phosphorus is less than 5.5 mg / dL.

[0098] Subjects will receive a dose reduction of 30 mcg per day (one ERC capsule) at any time if plasma iPTH is confirmed to be less than 30 pg / mL, corrected serum calcium is confirmed to be greater than 10.3 mg / dL, or serum phosphorus is confirmed to be greater than 5.5 mg / dL, provided that the increase in serum phosphorus is deemed related to study drug administration by the investigator. If a dose reduction is required for subjects receiving a minimum dose of 30 mcg per day, subjects will discontinue treatment and resume at the minimum dose of 30 mcg per day when iPTH is ≥ 30 pg / mL and corrected serum calcium is less than 9.8 mg / dL. Subjects receiving a minimum dose of 30 mcg per day who require a second dose interruption will discontinue further treatment with ERC capsules and immediately enter a FU period. Dose escalation is not permitted at any time after a dose reduction.

[0099] Subjects assigned to ERC capsules will be discontinued if plasma iPTH is confirmed to be less than 15 pg / mL or corrected serum calcium is confirmed to be greater than 11.0 mg / dL and will be resumed at a reduced dose of 30 mcg per day or a minimum dose of 30 mcg per day when plasma iPTH is ≥ 30 pg / mL and corrected serum calcium is less than 9.8 mg / dL. Subjects will receive 3 placebo capsules per day during any period of discontinuation.

[0100] Subjects will not receive any vitamin D and / or bone metabolism therapy other than ERC and vitamin D supplementation at a rate of 3,000 IU or less per day. Excluded therapies include 1α-hydroxylated vitamin D analogs (calcitriol, paricalcitol, and doxercalciferol), cinacalcet, bisphosphonates, denosumab, teriparatide, preotact, calcitonin, and other drugs that may affect bone metabolism. Glucocorticoid and hormone replacement therapy will remain at the same dose throughout the study. Use of calcium supplements or calcium-based antacid therapy such as calcium carbonate or calcium acetate will be permitted up to 1000 mg of elemental calcium per day. There are no study-specific dietary restrictions. Subjects will follow any dietary plan prescribed. Subjects will maintain their usual patterns of sun exposure and activity.

[0101] After treatment, all treated subjects demonstrate that serum total 25-hydroxyvitamin D concentrations remain essentially stable with continued dosing and rise to approximately 50-100 ng / mL with 25-hydroxyvitamin D3 treatment or to approximately 5-25 ng / mL with vitamin D3 treatment. In patients treated with 25-hydroxyvitamin D3, the incidence of hypocalcemia and the severity of secondary hyperparathyroidism are significantly reduced once stable dosing is achieved. However, hypocalcemia and secondary hyperparathyroidism occur more frequently in patients treated with cholecalciferol. After 12 months of treatment, patients treated with sustained-release 25-hydroxyvitamin D3 have higher and more consistent serum concentrations of 25-hydroxyvitamin D3 and lower plasma iPTH concentrations than patients treated with cholecalciferol. Patients treated with sustained-release 25-hydroxyvitamin D3 experienced substantial increases in bone mineral density compared with minimal changes or decreases in bone mineral density in patients treated with cholecalciferol.Data from this study demonstrate that treatment with sustained-release 25-hydroxyvitamin D3 is effective in normalizing serum total 25-hydroxyvitamin D, reducing plasma iPTH elevations, and increasing bone mineral density without causing unacceptable side effects related to calcium, phosphorus, or FGF23 metabolism.

[0102] The foregoing description is given for clarity of understanding only, and no unnecessary limitations should be understood therefrom, since modifications within the scope of the invention may be apparent to those skilled in the art.

[0103] Throughout this specification and the claims that follow, unless the context requires otherwise, the term "comprise", and variations such as "comprises" and "comprising", will be understood to mean the inclusion of a stated integer or step, or group of integers or steps, but not to the exclusion of any other integers or steps, or group of integers or steps.

[0104] Throughout this specification, when a composition is described as comprising a component or material, it is contemplated that the composition essentially consists of, or may consist of, any combination of the listed components or materials, unless otherwise stated.Similarly, when a method is described as comprising a particular step, it is contemplated that the method essentially consists of, or may consist of, any combination of the listed steps, unless otherwise stated.The inventions illustratively disclosed herein may be suitably practiced in the absence of any element or step not specifically disclosed herein.

[0105] The implementation of the methods disclosed herein, and their individual steps, may be performed manually and / or with the aid of automation provided by electronic devices. Although the process has been described with respect to a specific embodiment, those skilled in the art will readily recognize that other means of performing the acts associated with the method may be used. For example, the order of various steps may be changed without departing from the scope or spirit of the method, unless otherwise stated. In addition, some of the individual steps may be combined, omitted, or further subdivided into additional steps.

[0106] All patents, publications, and references cited herein are hereby incorporated by reference in their entirety. In the event of any inconsistency between this disclosure and the incorporated patents, publications, and references, this disclosure shall control.

Claims

1. A pharmaceutical composition for treating secondary hyperparathyroidism in bariatric surgery patients with a BMI greater than 30, comprising an effective amount of 25-hydroxyvitamin D3 in a sustained release oral dosage form.

2. The pharmaceutical composition of claim 1 for further treating vitamin D insufficiency and / or vitamin D deficiency in said patient.

3. The pharmaceutical composition according to claim 2 for treating refractory vitamin D deficiency.

4. The pharmaceutical composition according to any one of claims 1 to 3 for further treating or preventing osteomalacia in said patient.

5. The pharmaceutical composition according to any one of claims 1 to 4 for further treating or preventing renal osteodystrophy in said patient.

6. A pharmaceutical composition according to any one of claims 1 to 5 for further treating or preventing osteitis fibrosa cystica in said patient.

7. The pharmaceutical composition according to any one of claims 1 to 6 for further treating or preventing osteoporosis in said patient.

8. The pharmaceutical composition according to any one of claims 1 to 7 for further treating or preventing extraskeletal calcification in said patient.

9. The pharmaceutical composition according to any one of claims 1 to 8, for further treating or preventing bone pain in said patient.

10. The pharmaceutical composition according to any one of claims 1 to 9 for further treating or preventing periarthritis in said patient.

11. The pharmaceutical composition according to any one of claims 1 to 10 for further treating or preventing Mockerberg sclerosis in said patient.

12. The pharmaceutical composition according to any one of claims 1 to 11 for further treating or preventing muscle weakness in said patient.

13. The pharmaceutical composition according to any one of claims 1 to 12 for further treating or preventing growth retardation in said patient.

14. The pharmaceutical composition according to any one of claims 1 to 13 for further treating or preventing skeletal deformities in said patient.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the bariatric surgery includes a malabsorptive component.

16. The pharmaceutical composition of any one of claims 1 to 15, wherein the bariatric surgery includes a bypass component.

17. 17. The pharmaceutical composition of claim 16, wherein at least the patient's duodenum is bypassed.

18. 20. The pharmaceutical composition of claim 17, wherein at least the patient's duodenum and at least a portion of the patient's jejunum are bypassed.

19. 20. The pharmaceutical composition of claim 18, wherein at least the duodenum and jejunum of the patient are bypassed.

20. The pharmaceutical composition of any one of claims 1 to 19, wherein the bariatric surgery patient is undergoing Roux-en-Y surgery.

21. The pharmaceutical composition according to any one of claims 1 to 20, for preoperative administration.

22. 22. The pharmaceutical composition of any one of claims 1 to 21, for increasing the patient's serum total 25-hydroxyvitamin D3 to greater than 30 ng / mL, or greater than 50 ng / mL, or in the range of 50 ng / mL to 90 ng / mL, or greater than 100 ng / mL, or in the range of 100 ng / mL to 200 ng / mL.

23. The pharmaceutical composition according to any one of claims 1 to 22, for reducing the plasma intact parathyroid hormone concentration in said patient by at least 30%.

24. 24. The pharmaceutical composition of any one of claims 1 to 23, wherein the patient is an adult patient, for lowering the plasma intact parathyroid hormone concentration in the patient to a range of 10 pg / mL to 65 pg / mL.

25. 24. The pharmaceutical composition of any one of claims 1 to 23, wherein the patient is a pediatric patient, for lowering the plasma intact parathyroid hormone concentration in the patient to a range of 9 pg / mL to 52 pg / mL.

26. The pharmaceutical composition according to any one of claims 1 to 25, for increasing bone mineral density in said patient.

27. The pharmaceutical composition according to any one of claims 1 to 26, for reducing the blood concentration of a bone resorption marker in the patient.

28. 28. The pharmaceutical composition of claim 27, wherein the bone resorption marker is one or more markers selected from PTHrP, FGF23, NTX, CTX, and TRAP-5b.

29. 29. The pharmaceutical composition of claim 27 or 28, wherein the reduction is to within the normal reference range of the marker.

30. The pharmaceutical composition of any one of claims 27 to 29, wherein the reduction is at least about 10%, or at least about 20%, or at least about 30%.

31. The pharmaceutical composition according to any one of claims 1 to 30, for reducing the blood concentration of a bone formation marker in the patient.

32. The pharmaceutical composition of claim 31 , wherein the bone formation marker is one or more markers selected from BAP and P1NP.

33. 33. The pharmaceutical composition of claim 31 or 32, wherein the reduction is to within the normal reference range of the marker.

34. The pharmaceutical composition of any one of claims 31 to 33, wherein the reduction is at least about 10%, or at least about 20%, or at least about 30%.

35. 35. The pharmaceutical composition of any one of claims 1 to 34, wherein the oral dosage form comprises 25-hydroxyvitamin D3 in an amount ranging from 1 μg to 1000 μg.

36. A pharmaceutical composition according to any one of claims 1 to 35, wherein said treatment simultaneously avoids the occurrence of hypocalcemia in said patient.

37. A pharmaceutical composition according to any one of claims 1 to 36, wherein said treatment simultaneously avoids the occurrence of hypercalcemia in said patient.

38. The pharmaceutical composition of any one of claims 1 to 37, wherein said treatment simultaneously avoids an increase in FGF23 in said patient.

Citation Information

Patent Citations

  • Controlled-release oral composition containing a vitamin D compound and a waxy carrier

    JP2010525078A

  • Stabilized modified release vitamin d formulations and methods of administration thereof

    JP2016517429A

  • Vitamin D therapy

    JP2019510045A

  • Transdermal delivery formulation

    WO2016205245A1

  • Methods of vitamin d treatment

    WO2017182237A1